TABLE 6.
RDV antiviral activity against SARS-CoV-2 in A549-hACE2 cells in the presence of a CatA inhibitor
| Parameter | Antiviral activity of: |
||||
|---|---|---|---|---|---|
| RDVa | Telaprevir | RDV + 0.5 μM telaprevir | RDV + 2.5 μM telaprevir | RDV + 10 μM telaprevir | |
| EC50 (nM)b | 99 ± 17 | >50,000 | 166 ± 8 | 223 ± 24 | 285 ± 29 |
| Fold-RDV EC50b,c | 1.70 ± 0.19 | 2.27 ± 0.25 | 2.91 ± 0.65 | ||
a
Cultures were treated with RDV and DMSO to the same final concentration of DMSO as cultures treated with telaprevir. Cellular toxicity was monitored in parallel using CellTiter-Glo (Promega). Minimal loss of cell viability was detected at the highest concentrations of compounds tested, with the exception of telaprevir, where a CC50 of 29.2 μM was observed.
b
Values represent average ± standard deviation of three independent measurements.
c
Fold-RDV EC50 was calculated by dividing the EC50 of the telaprevir combination treatment by the EC50 of RDV (plus DMSO). Presented are the average fold-RDV EC50 of three individual experiments.